Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1/2 6Phase 3 2Phase 1 2Phase 2/3 1

Status

Completed 6Recruiting 3Not yet recruiting 2Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1

Interventions

Paclitaxel 24Oxaliplatin 24Capecitabine 24Gemcitabine 21Cisplatin 21Fluorouracil 20Drug Therapy 18Docetaxel 18Carboplatin 17pembrolizumab 15Leucovorin 15Irinotecan 15Radiotherapy 12tislelizumab 11Magnetic Resonance Spectroscopy 10Bevacizumab 10Specimen Handling 9Pemetrexed 9Radiation 8Injections 8Cetuximab 8toripalimab 7Surgical Procedures, Operative 7Radiotherapy, Intensity-Modulated 7Azacitidine 7venetoclax 6sintilimab 6Trastuzumab 6Topotecan 6Standard of Care 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × irinotecan sucrosofate × Clear all
NCT06571461 2024-08-27

Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as Postoperative Adjuvant Therapy for Pancreatic Cancer

CSPC Ouyi Pharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
408 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT06501664 2024-07-15

Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC

Sun Yat-sen University

Phase 3 Not yet recruiting
360 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡